The earnings call highlighted robust revenue growth, particularly in Testing Services and Patient & Digital Solutions, alongside significant operational improvements. However, potential challenges due to the draft LCD policy and a delay in the EPIC rollout were noted as concerns.

Company Guidance -

Q3 2025

During the CareDx Second Quarter 2025 Earnings Call, the company provided updated guidance for the fiscal year. CareDx reaffirmed the midpoint of its 2025 revenue guidance, narrowing the range to $367 million to $373 million, and maintained expectations for adjusted EBITDA between $29 million and $33 million. In the second quarter, adjusted revenue was reported at $90.5 million, marking a 14% year-over-year increase, while adjusted EBITDA reached $9.1 million, compared to a loss of $300,000 in the previous year. The company delivered approximately 49,500 tests, reflecting a 13% increase from the prior year, and highlighted a 20% year-over-year growth in kidney testing volume. CareDx also discussed potential impacts of draft policy scenarios, estimating a $15 million to $30 million headwind depending on the finalization of the draft policy surrounding testing frequency and bundled payments.

Strong Revenue Growth

Adjusted revenue was $90.5 million, up 14% year-over-year. Testing Services revenue also increased by 14% year-over-year, with an eighth consecutive quarter of sequential testing volume growth.

Kidney Testing Volume Growth

Kidney testing volume grew nearly 20% year-over-year, with significant progress in expanding surveillance testing protocols.

Operational Improvements

Implemented 100% of RCM workflows, resulting in a 60% reduction in claim submission time, a 45% increase in prior authorization success rate, and other substantial improvements in revenue cycle management KPIs.

Patient & Digital Solutions Growth

Reported revenue of $12.8 million, representing a 19% growth compared to last year, driven by an effective go-to-market strategy.

Lab Products Revenue Increase

Lab Products revenue was $11.8 million, up 12% year-over-year, driven by sales of AlloSeq Tx kits.

CareDx (CDNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CDNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.08 / -	-0.14	―	―	―
Aug 06, 2025	2025 (Q2)	-0.10 / -0.16	-0.03	-433.33% (-0.13)
Apr 30, 2025	2025 (Q1)	-0.21 / -0.19	-0.32	40.63% (+0.13)
Feb 26, 2025	2024 (Q4)	-0.41 / 1.51	-2.21	168.33% (+3.72)
Nov 04, 2024	2024 (Q3)	-0.25 / -0.14	-0.43	67.44% (+0.29)
Jul 31, 2024	2024 (Q2)	-0.40 / -0.03	-0.46	93.48% (+0.43)
May 09, 2024	2024 (Q1)	-0.47 / -0.32	-0.44	27.27% (+0.12)	―
Feb 28, 2024	2023 (Q4)	-0.45 / -2.21	-0.34	-550.00% (-1.87)	―
Nov 08, 2023	2023 (Q3)	-0.59 / -0.43	-0.32	-34.37% (-0.11)	―
Aug 08, 2023	2023 (Q2)	-0.55 / -0.46	-0.41	-12.20% (-0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CDNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$13.10	$12.07	-7.86%
Apr 30, 2025	$16.88	$15.07	-10.72%
Feb 26, 2025	$21.10	$21.06	-0.19%
Nov 04, 2024	$22.93	$22.90	-0.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.